Alzheimer's Disease Clinical Trials

Conceptual Processing in Alzheimer’s Disease

The purpose of this study is to evaluate memory, language and cognitive difficulties in patients with AD. AD is a neurological disease where a specific part of the brain is not functioning well. A clinical diagnosis of AD needs to be confirmed in all participants prior to participation in the …

The Neural Basis for Frontotemporal Degeneration

The purpose of this research study is to develop a better understanding of the genetic causes for frontotemporal degeneration (FTD), as well as Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA). These conditions include difficulty with language and speaking, organization and planning, memory, and/or a behavior or personality change. …

None

None

None

None

Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)

It is a non-treatment clinical research study to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.Data from this research will help determine the best measures for diagnosis and disease monitoring , which will be used to accelerate the testing of therapeutic interventions and …

Phase II Study to Assess the Safety Tolerability and Target Engagement of AMX0035 a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimers Disease

This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways.

A Pilot Study to Evaluate the Effect of CT1812 Treatment on A-beta Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease

Cognition Therapeutics is developing an oral formulation of CT1812 to treat AD and mild cognitive impairment. This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD, sponsored by the NIH.

A phase 2b double-blind randomised 5-arm vehicle-controlled dose ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1 3 8 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis.

The purpose of this clinical trial is to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects atopic dermatitis (a type of eczema). key eligibility include: Age 18 years and above. Diagnosis of AD …